Jpmorgan Chase & CO Cerevel Therapeutics Holdings, Inc. Transaction History

Jpmorgan Chase & CO

$1.22 Trillion
Q3 2024

16 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Dec 26, 2024	BUY	$38.96 - $42.75 $27.2 Million - $29.8 Million	697,510 New	697,510 $28.5 Million
Q2 2024 Aug 12, 2024	BUY	$38.96 - $42.75 $10 Million - $11 Million	257,344 Added 58.47%	697,510 $28.5 Million
Q1 2024 Dec 26, 2024	BUY	$40.88 - $43.27 $18 Million - $19 Million	440,166 New	440,166 $18.6 Million
Q1 2024 May 10, 2024	BUY	$40.88 - $43.27 $11.6 Million - $12.3 Million	283,358 Added 180.7%	440,166 $18.6 Million
Q4 2023 Dec 26, 2024	BUY	$20.27 - $42.44 $3.18 Million - $6.65 Million	156,808 New	156,808 $6.65 Million
Q4 2023 Feb 12, 2024	BUY	$20.27 - $42.44 $1.21 Million - $2.53 Million	59,523 Added 61.18%	156,808 $6.65 Million
Q3 2023 Nov 14, 2023	SELL	$20.26 - $31.91 $1.3 Million - $2.04 Million	-64,066 Reduced 39.71%	97,285 $2.12 Million
Q2 2023 Aug 11, 2023	SELL	$23.9 - $35.38 $32,097 - $47,515	-1,343 Reduced 0.83%	161,351 $5.13 Million
Q1 2023 May 18, 2023	BUY	$22.82 - $35.32 $1.82 Million - $2.82 Million	79,721 Added 96.08%	162,694 $3.97 Million
Q1 2023 May 11, 2023	SELL	$22.82 - $35.32 $1.1 Million - $1.7 Million	-47,999 Reduced 36.65%	82,973 $2.02 Million
Q4 2022 Feb 13, 2023	BUY	$25.35 - $31.96 $12,624 - $15,916	498 Added 0.38%	130,972 $4.13 Million
Q3 2022 Nov 14, 2022	BUY	$25.5 - $41.42 $1.82 Million - $2.96 Million	71,361 Added 120.72%	130,474 $3.69 Million
Q2 2022 Aug 11, 2022	BUY	$20.62 - $37.15 $224,902 - $405,195	10,907 Added 22.63%	59,113 $1.56 Million
Q1 2022 May 11, 2022	BUY	$23.5 - $35.38 $128,474 - $193,422	5,467 Added 12.79%	48,206 $1.69 Million
Q4 2021 Feb 10, 2022	BUY	$29.21 - $44.64 $389,807 - $595,720	13,345 Added 45.4%	42,739 $1.39 Million
Q3 2021 Nov 12, 2021	BUY	$21.26 - $38.85 $624,916 - $1.14 Million	29,394 New	29,394 $868,000

Others Institutions Holding CERE

# of Institutions

Shares Held

5.01M

Call Options Held

3.3K

Put Options Held

View Full List

About Cerevel Therapeutics Holdings, Inc.

Ticker CERE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 155,752,000
Description
Cerevel Therapeutics Holdings, Inc., a clinical-stage biopharmaceutical company, engages in the development of various therapies for neuroscience diseases. It is developing emraclidine, a positive allosteric modulator (PAM) that is in phase 1b clinical trials for the treatment of schizophrenia; and Darigabat, a PAM, which is in Phase 2 proof-of-...

More about CERE

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Jpmorgan Chase & CO, based on Form 13F filings with the SEC.

News

Stay updated on Jpmorgan Chase & CO with notifications on news.

Account